Managing Aromatase Inhibitors in Breast Cancer Survivors: Not Just for Oncologists
Managing Aromatase Inhibitors in Breast Cancer Survivors: Not Just for Oncologists Longer duration of endocrine therapy up to 10 years in high risk cases of hormone receptor positive breast cancer…